Drugs / RSVPreF3 formulation 2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04138056 | Nov 2019 → Feb 2020 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSVPreF3 formulation 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04138056 ↗ |
| Modality | Vaccine | “RSVPreF3 formulation 2 vaccine” NCT04138056 ↗ |
| Route | Intramuscular | “administered intramuscularly in the left arm” NCT04138056 ↗ |